Lestaurtinib Completed Phase 2 Trials for Polycythemia Vera (PV) / Essential Thrombocythemia (ET) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00586651Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis